Trial Profile

A Phase 1 Study to Evaluate the Effect of MLN0128 on the QTc Interval in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sapanisertib (Primary)
Indications Anal cancer; Cervical cancer; Colon cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Sarcoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Thyroid cancer
Focus Adverse reactions
Sponsors Calithera Biosciences; Takeda Oncology

Most Recent Events

20 Mar 2019 Status changed from active, no longer recruiting to completed.
02 Feb 2019 Planned End Date changed from 30 Jan 2019 to 28 Feb 2019.
21 Jan 2019 Planned End Date changed from 21 Dec 2018 to 30 Jan 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com